GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy ...

In today’s CEO Daily: Diane Brady talks to GoodRx CEO Wendy Barnes. The big story: Trump, Putin, and Zelensky headed for ...

Starting today, eligible patients can use GoodRx to self-pay for Ozempic ® and Wegovy ® pens for $499-per-month at over ...

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

A number of stocks fell in the afternoon session after the major indices continued to pull back, with technology stocks ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both of Novo Nordisk's GLP-1 drugs, Ozempic ...

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...

Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company announced a ...

Investing.com -- GoodRx (NASDAQ: GDRX) stock surged 18% after announcing a collaboration with Novo Nordisk (NYSE: NVO) to offer Ozempic and Wegovy to eligible self-paying patients for $499 per month.

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...